4 results
To assess the bioequivalence of 6 mg dexamethasone tablet administered PO as an alternative to 5,26 mg dexamethasone-disodiumphosphate (= 4 mg dexamethasone) solution administered IV
Primary- To evaluate the safety and tolerability of long-term intermittent use of lasmiditan for the acute treatment of migraine in pediatric patients.Key Secondary- To evaluate the efficacy of intermittently dosed lasmiditan in the treatment of…
Primary: - To evaluate the efficacy of 2 dose quantities of lasmiditan on migraine headache pain freedom compared to placebo - To evaluate the consistency of response to 2 dose quantities of lasmiditan compared to placeboSecondary: - To evaluate the…
Primary- To test the hypothesis that lasmiditan high dose is superior to placebo in the acute treatment of a migraine attack in pediatric patients >=6 to <18 years of ageKey Secondary- To test the hypothesis that lasmiditan medium dose…